A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorialZFTA-fused ependymoma
Open Access
- 1 January 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 5 (1) , vdad057
Abstract
ZFTA-RELA (formerly known as c11orf-RELA) fused supratentorial ependymoma (ZFTAfus ST-EPN) has been recognized as a novel entity in the 2016 WHO classification of CNS tumors and further defined in the recent 2021 edition. ZFTAfus ST-EPN was reported to portend poorer prognosis when compared to its counterpart, YAP1 ST-EPN in some previously published series. The aim of this study was to determine the treatment outcome of molecularly confirmed and conventionally treated ZFTAfus ST-EPN patients treated in multiple institutions. We conducted a retrospective analysis of all pediatric patients with molecularly confirmed ZFTAfus ST-EPN patients treated in multiple institutions in 5 different countries (Australia, Canada, Germany, Switzerland, and Czechia). Survival outcomes were analyzed and correlated with clinical characteristics and treatment approaches. A total of 108 patients were collated from multiple institutions in 5 different countries across three continents. We found across the entire cohort that the 5- and 10-year PFS were 65% and 63%, respectively. The 5- and 10-year OS of this cohort of patients were 87% and 73%. The rates of gross total resection (GTR) were high with 84 out of 108 (77.8%) patients achieving GTR. The vast majority of patients also received post-operative radiotherapy, 98 out of 108 (90.7%). Chemotherapy did not appear to provide any survival benefit in our patient cohort. This is the largest study to date of contemporaneously treated molecularly confirmed ZFTAfus ST-EPN patients which identified markedly improved survival outcomes compared to previously published series. This study also re-emphasizes the importance of maximal surgical resection in achieving optimal outcomes in pediatric patients with supratentorial ependymoma.Keywords
Funding Information
- McClurg Foundation
- Hospital Research Foundation
- Robert Connor Dawes Foundation
This publication has 26 references indexed in Scilit:
- A Global View on the Availability of Methods and Information in the Neuropathological Diagnostics of CNS Tumors: Results of an International Survey Among Neuropathological UnitsBrain Pathology, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age GroupsCancer Cell, 2015
- C11orf95–RELA fusions drive oncogenic NF-κB signalling in ependymomaNature, 2014
- Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trialJournal of Neuro-Oncology, 2013
- Infant Ependymoma in a 10-Year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) Experience With Omitted or Deferred RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Molecular Staging of Intracranial Ependymoma in Children and AdultsJournal of Clinical Oncology, 2010
- Conformal radiotherapy after surgery for paediatric ependymoma: a prospective studyThe Lancet Oncology, 2009
- Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective studyThe Lancet Oncology, 2007
- Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric OncologyJournal of Clinical Oncology, 2001